{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_17292", "batch_size": 260, "batch_pos": 64, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment uses neutral language without high-potency verbs, metaphors, superlatives, or critical alert phrases.", "method": "llm_batch", "batch_id": "batch_2_18200", "batch_size": 260, "batch_pos": 35, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment makes a factual statement about advantages ('offers advantages') and a past event ('demonstrated during the COVID-19 pandemic') which are not Q3 Alarmist cues.", "method": "llm_batch", "batch_id": "batch_3_3044", "batch_size": 260, "batch_pos": 240, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment contains factual statements, not a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_16808", "batch_size": 260, "batch_pos": 230, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment reports advantages of technology but contains no explicit calming cue.", "method": "llm_batch", "batch_id": "batch_5_16820", "batch_size": 260, "batch_pos": 225, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser word combined with an explicit scale contrast.", "method": "llm_batch", "batch_id": "batch_6_15404", "batch_size": 260, "batch_pos": 192, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "Segment contains no bare negation.", "method": "llm_batch", "batch_id": "batch_7_18388", "batch_size": 260, "batch_pos": 184, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "Describes the advantages of a technology (capability) without active reassurance.", "method": "llm_batch", "batch_id": "batch_8_13672", "batch_size": 260, "batch_pos": 6, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
